Mark Huffman, MD, Professor of Medicine of Cardiology and Co-Director of the Global Health Center and Anubha Agarwal, MD, Assistant Professor of Medicine of Cardiology and Co-Director Program in Global Cardiovascular Health announced that the WHO have included the Polypill on their Model List of essential medicines (EML). “Essential medicines are those that satisfy the priority health care needs of a population,” the report says. “They are intended to be available in functioning health systems at all times, in appropriate dosage forms, of assured quality and at prices individuals and health systems can afford.”
Using polypills to treat cardiovascular diseases and other conditions is now recommended for the first time in the guidelines. Polypills combine blood pressure medications, cholesterol lowering statins, medications to reduce heart beat force and aspirin is a way to treat heart issues.
Polypill Cardiovascular Medicines
Fixed-dose combinations of multiple medicines (commonly called ‘polypills’) for the prevention of diseases of the heart and blood vessels, notably cholesterol-lowering agents with one or more blood pressure lowering agents with and without acetylsalicylic acid (aspirin) have been added to the EML for the first time. Based on recommendations by previous EML Expert Committees, scientists from multiple countries conducted milestone trials confirming the benefit of these combinations for both primary and secondary prevention of heart disease.